Zura Bio (NASDAQ:ZURA) Shares Down 7.2% - Time to Sell?

Key Points

• Zura Bio shares fell 7.2% to about $5.69, with trading volume below average. The company has a market capitalization of approximately $547 million and remains unprofitable, reporting a quarterly loss of $0.21 per share.
• Analyst sentiment is generally positive despite the decline: the stock has a consensus “Moderate Buy” rating and a $17 average price target, well above its current price. However, one ratings firm maintains a sell assessment.
• Institutional ownership is substantial at 61.14%, with several hedge funds recently establishing or increasing positions. Zura Bio is a clinical-stage biotechnology company developing protein-conjugate technologies for oncology, immunology and rare-disease applications.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) fell 7.2% during trading on Wednesday . The company traded as low as $5.71 and last traded at $5.6860. Approximately 516,569 shares changed hands during trading, a decline of 44% from the average daily volume of 920,024 shares. The stock had previously closed at $6.13.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wedbush lifted their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Guggenheim boosted their price target on shares of Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zura Bio in a report on Monday, July 6th. William Blair initiated coverage on Zura Bio in a report on Wednesday, July 8th. They set an "outperform" rating on the stock. Finally, Wall Street Zen raised Zura Bio from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Zura Bio has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Zura Bio Stock Performance

The company's fifty day moving average is $5.59 and its 200-day moving average is $5.37. The company has a market capitalization of $546.71 million, a PE ratio of -5.05 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. On average, sell-side analysts expect that Zura Bio Limited will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. EcoR1 Capital LLC acquired a new position in shares of Zura Bio in the first quarter worth $7,019,000. Siren L.L.C. grew its holdings in shares of Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock worth $22,222,000 after acquiring an additional 2,434,866 shares during the period. Stempoint Capital LP purchased a new position in Zura Bio in the 1st quarter valued at about $4,483,000. Montanova Capital LLC lifted its stake in shares of Zura Bio by 4.1% in the 2nd quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock valued at $55,714,000 after purchasing an additional 376,000 shares in the last quarter. Finally, Commodore Capital LP purchased a new stake in shares of Zura Bio in the first quarter worth about $19,338,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.